NASDAQ: TRVITrevi Therapeutics Inc Stock
$6.91+0.60 (+9.51%)
Updated Apr 30, 2025
TRVI Price
$6.91
Fair Value Price
$0.33
Market Cap
$668.07M
52 Week Low
$2.30
52 Week High
$7.39
P/E
-14.7x
P/B
6.7x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$47.91M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$38M
Beta
0.74
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TRVI Overview
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TRVI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TRVI
Ranked#273 of 462
Ranked#273 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important TRVI news, forecast changes, insider trades & much more!
TRVI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRVI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRVI ($6.91) is overvalued by 2,011.59% relative to our estimate of its Fair Value price of $0.33 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TRVI ($6.91) is not significantly undervalued (2,011.59%) relative to our estimate of its Fair Value price of $0.33 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TRVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TRVI due diligence checks available for Premium users.
Valuation
TRVI fair value
Fair Value of TRVI stock based on Discounted Cash Flow (DCF)
Price
$6.91
Fair Value
$0.33
Overvalued by
2,011.59%
TRVI ($6.91) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TRVI ($6.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TRVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TRVI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-14.7x
Industry
-162.28x
Market
29.18x
TRVI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.7x
Industry
4.45x
TRVI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TRVI's financial health
Profit margin
Revenue
$0.0
Net Income
-$11.4M
Profit Margin
0%
TRVI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$110.9M
Liabilities
$11.3M
Debt to equity
0.11
TRVI's short-term assets ($109.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRVI's short-term assets ($109.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRVI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TRVI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.6M
Investing
-$23.9M
Financing
$51.5M
TRVI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TRVI vs Biotech Stocks
Trevi Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.